BACKGROUND: Over half of all HIV-infected adults are women and heterosexual intercourse is a significant mode of viral transmission. This review examines the potential for using polymeric vaginal ring systems to provide controlled delivery of HIV microbicides in order to prevent heterosexual transmission of the virus. DISCUSSION: Continuous delivery of microbicides has the potential to be more effective than one-off dosing. Thus, controlled-release vaginal delivery devices are now a key area of HIV prevention research. Initial clinical trials on vaginal rings loaded with dapivirine (a candidate microbicide) have indicated that these products are safe and well tolerated by women. These devices are female-initiated, robust and capable of long-term delivery of the active agent. CONCLUSIONS: Vaginal rings may offer an effective system for the controlled delivery of microbicides to prevent heterosexual transmission of HIV. Candidate vaginal ring microbicide products are now in clinical trials.
BACKGROUND: Over half of all HIV-infected adults are women and heterosexual intercourse is a significant mode of viral transmission. This review examines the potential for using polymeric vaginal ring systems to provide controlled delivery of HIV microbicides in order to prevent heterosexual transmission of the virus. DISCUSSION: Continuous delivery of microbicides has the potential to be more effective than one-off dosing. Thus, controlled-release vaginal delivery devices are now a key area of HIV prevention research. Initial clinical trials on vaginal rings loaded with dapivirine (a candidate microbicide) have indicated that these products are safe and well tolerated by women. These devices are female-initiated, robust and capable of long-term delivery of the active agent. CONCLUSIONS: Vaginal rings may offer an effective system for the controlled delivery of microbicides to prevent heterosexual transmission of HIV. Candidate vaginal ring microbicide products are now in clinical trials.
Authors: Christopher McConville; James M Smith; Clare F McCoy; Priya Srinivasan; James Mitchell; Angela Holder; Ron A Otten; Salvatore Butera; Gustavo F Doncel; David R Friend; R Karl Malcolm Journal: Drug Deliv Transl Res Date: 2015-02 Impact factor: 4.617
Authors: Meredith R Clark; Patrick F Kiser; Andrew Loxley; Christopher McConville; R Karl Malcolm; David R Friend Journal: Drug Deliv Transl Res Date: 2011-06 Impact factor: 4.617
Authors: Todd J Johnson; Meredith R Clark; Theodore H Albright; Joel S Nebeker; Anthony L Tuitupou; Justin T Clark; Judit Fabian; R Tyler McCabe; Neelima Chandra; Gustavo F Doncel; David R Friend; Patrick F Kiser Journal: Antimicrob Agents Chemother Date: 2012-09-24 Impact factor: 5.191
Authors: Sten H Vermund; Sarah J Fidler; Helen Ayles; Nulda Beyers; Richard J Hayes Journal: J Acquir Immune Defic Syndr Date: 2013-07 Impact factor: 3.731
Authors: Diarmaid J Murphy; Katie Amssoms; Geert Pille; Aileen Clarke; Marc O'Hara; Jens van Roey; R Karl Malcolm Journal: Drug Deliv Transl Res Date: 2016-06 Impact factor: 4.617
Authors: Justin T Clark; Meredith R Clark; Namdev B Shelke; Todd J Johnson; Eric M Smith; Andrew K Andreasen; Joel S Nebeker; Judit Fabian; David R Friend; Patrick F Kiser Journal: PLoS One Date: 2014-03-05 Impact factor: 3.240